LAKEWOOD, Colo.,Aug. 1, 2023/PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole ...
“Reveos has a long-standing track record for helping blood centers globally meet the critical needs of patients while creating efficiencies in their operations,” Antoinette Gawin, Terumo’s president and CEO, said in a companyannouncementTuesday. With its new FDA clearance, the ...
By continuously striving to meet various needs in medical settings, Terumo has become a global company with its extensive business portfolio ranging from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical pract...
ADVANCED TECHNOLOGY THAT GIVES YOU CHOICE AND PRECISION Eciently manages targeted components Automated Interface Management (AIM) System Platelets, White Cells Using a patented optical detection system, the AIM system continuously manages the separated layers, allowing the platelet and white blood cell la...